Replies to post #3324 on Galectin Therapeutics Inc. (GALT)

[thefamilyman]

We can only hope. It’s also possible that MDGL’s PR has just attracted more eyes to the possible treatments for NASH.

[thefamilyman]

Another source citing BMY’s interest in NASH.

“Buying has perked up in certain stocks with exposure to non-alcoholic steatohepatitis (NASH) after Bristol-Myers Squibb's (BMY +0.8%) business development chief Paul Biondi said that the company is ‘actively looking for acquisitions or license opportunities’ in fibrotic diseases (per DealReporter).” - Douglas House

[thefamilyman]

Here is the link to the article referenced by IRAHopeful.

https://seekingalpha.com/article/4180041-galectin-therapeuticss-market-value-soar-coming-months